TORONTO, April 3, 2023 /PRNewswire/ - Greenbrook TMS Inc. (NASDAQ: GBNH) ("Greenbrook" or the "Company") today announced that the Company has amended its amended and restated master sales agreement ...
Credit: BrainsWay. The outpatient procedure provides noninvasive magnetic stimulation through a cushioned helmet to targeted areas of the brain. The Food and Drug Administration (FDA) has expanded the ...
NeuroStar Advanced Therapy is a transcranial magnetic stimulation system that uses magnetic fields to induce neural activity in the cerebral cortex. The Food and Drug Administration (FDA) has cleared ...
Please provide your email address to receive an email when new articles are posted on . The FDA has granted clearance to a transcranial magnetic stimulation device as an adjunctive treatment for major ...
A University of Iowa research team is aiming to treat conditions such as depression, anxiety, and post-traumatic stress ...
An advanced version of a procedure using magnetic fields to stimulate brain nerve cells in treating depression was significantly effective for 85% of active military and veterans suffering from combat ...
Neuronetics said the FDA cleared its transcranial magnetic stimulation (TMS) device, NeuroStar, as an adjunct therapy for the first-line treatment of major depressive disorder in individuals ages 15 ...
The US Food and Drug Administration (FDA) granted 510K clearance to market a new transcranial magnetic stimulation (TMS) device, the MagVita TMS Therapy system from MagVenture, for treatment of adults ...
An electromagnetic therapy for depression shouldn't damage a person's pre-existing implantable cardioverter-defibrillator (ICD), multiple experiments indicated. There was a low risk of ICD damage or ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results